N
EPRX

Natixis’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Natixis’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
+17,644
New +$122K ﹤0.01% 987

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Natixis's EPRX Position: Q2 2026 in Review

Natixis opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q2 2026: 17,644 shares worth $115K. The stake represents ﹤0.01% of the portfolio and ranks #987 among its holdings.

68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Natixis held 17,644 shares of Eupraxia Pharmaceuticals worth $115K as of Q2 2026.
  • Eupraxia Pharmaceuticals was a new Natixis position in Q2 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #987 holding.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.